Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 11/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17071866 | 0.84 | IDO1 (0.56) | IDO1SLC6A2SLC6A4P2RX7HDAC3 | |
| SCHEMBL3278237 | 0.83 | IDO1 (0.59) | IDO1SLC6A2SLC6A4P2RX7HDAC3 | |
| SCHEMBL8415469 | 0.83 | IDO1 (0.46) | IDO1SLC6A2SLC6A4P2RX7EPHX2 | |
| SCHEMBL12740308 | 0.83 | IDO1 (0.42) | IDO1SLC6A2SLC6A4P2RX7 | |
| SCHEMBL1538597 | 0.83 | IDO1 (0.63) | IDO1SLC6A2SLC6A4P2RX7HDAC3 | |
| SCHEMBL14378240 | 0.82 | IDO1 (0.50) | IDO1SLC6A2SLC6A4P2RX7HDAC3 | |
| SCHEMBL3278241 | 0.81 | IDO1 (0.61) | IDO1SLC6A2SLC6A4P2RX7HDAC3 | |
| SCHEMBL9969387 | 0.80 | IDO1 (0.56) | IDO1SLC6A2SLC6A4P2RX7HDAC3 | |
| SCHEMBL147045 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4P2RX7HDAC3 | |
| SCHEMBL17864241 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4P2RX7HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3636636-B1 | PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE | MITSUI CHEMICALS AGRO INC (JP) | 2022-07-06 | — | — | EP | disclosed |
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2022-05-03 | — | — | US | disclosed |
| WO-2021214048-A1 | DUAL INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND 5-LIPOXYGENASE | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2021-10-28 | — | — | WO | disclosed |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-09-09 | — | — | US | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| WO-2007145922-A2 | BENZAZEPINONES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| EP-1761529-B1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| WO-2007068418-A1 | USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | IDO1 4145/4885SLC6A2 4281/4885SLC6A4 4444/4885 |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | IDO1 782/4885SLC6A2 341/4885SLC6A4 612/4885 |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | CCR1, CCL2, CCL11 | IDO1 727/4885SLC6A2 4797/4885SLC6A4 4846/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | IDO1 782/4885SLC6A2 341/4885SLC6A4 612/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | IDO1 1995/4885SLC6A2 1103/4885SLC6A4 1052/4885 |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | IDO1 4720/4885SLC6A2 295/4885SLC6A4 723/4885 |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | IDO1 822/4885SLC6A2 262/4885SLC6A4 213/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | IDO1 4720/4885SLC6A2 295/4885SLC6A4 723/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | IDO1 28/4885SLC6A2 364/4885SLC6A4 773/4885 |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | TBXA2R, HTR2C, NPY1R | IDO1 742/4885SLC6A2 353/4885SLC6A4 290/4885 |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | IDO1 4145/4885SLC6A2 4281/4885SLC6A4 4444/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | IDO1 2315/4885SLC6A2 4848/4885SLC6A4 4810/4885 |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TRPC5, TRPC1, GOT1 | IDO1 184/4885SLC6A2 576/4885SLC6A4 208/4885 |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | IDO1 3624/4885SLC6A2 4608/4885SLC6A4 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.